文献速递消化道肿瘤放疗放疗物理与技术

细胞外容积分数预测胰腺癌放化疗疗效

Predicting Treatment Response From Extracellular Volume Fraction for Chemoradiation Therapy of Pancreatic Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-10-07

研究纳入25例接受术前放化疗(50.4 Gy/28次)的胰腺癌患者,利用双能CT计算肿瘤细胞外容积分数(ECVf),并与治疗前后CA19-9变化进行相关性分析。结果显示ECVf与CA19-9变化呈线性相关(R²=0.7,P=.006),提示基于双源双能CT碘图的ECVf或可用于预测新辅助放化疗后的治疗反应。

要点

  • 25例胰腺癌患者术前放化疗期间,ECVf与CA19-9变化呈线性相关(R²=0.7,P=.006)。
  • 双能CT来源碘浓度与体模测量一致(R²=1.0)。
  • 基于双源双能CT碘图计算的ECVf或可预测新辅助放化疗后的治疗反应。

核心结论

  • 基于双源双能CT碘图计算的ECVf或可用于预测胰腺癌新辅助放化疗后的治疗反应。

研究设计与样本

  • 研究分析了25例胰腺癌患者在标准放疗模拟定位时于双源双能CT模拟机获得的晚动脉期双能CT数据及其CA19-9和血细胞比容数据。
  • 每例患者接受术前放化疗,处方剂量为50.4 Gy分28次。
  • 患者基于胰腺内存在可清晰勾画的实性肿瘤而入选。

主要发现

  • 双能CT来源碘浓度与体模测量一致(R²=1.0)。
  • 25例患者治疗期间平均血细胞比容为35.6 ± 5.4%,平均ECVf为7.3 ± 4.9%,CA19-9平均变化为-4.6 ± 21.8。
  • ECVf与CA19-9变化呈线性相关,R²为0.7:ΔCA19-9 = 3.63 × ECVf - 31.1。
  • 该相关性有统计学意义(P = .006)。

关键数值与推荐

  • ECVf由感兴趣区(ROI)内双能CT计算的碘密度与模拟定位时血细胞比容的比值计算得出。
  • ROI置于肿瘤和主动脉内。
  • 术前再分期影像排除远处转移作为CA19-9升高的原因。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Dual-energy computed tomography (DECT) data can be used to calculate the extracellular volume fraction (ECVf) in tumors, which has been correlated with treatment outcome. This study sought to find a correlation between ECVf and treatment response as measured by the change in cancer antigen (CA) 19 to 9 during chemoradiation therapy (CRT) for pancreatic cancer. METHODS AND MATERIALS: Dual-energy CT data acquired during the late arterial contrast phase in the standard radiation therapy simulation on a dual-source DECT simulator for 25 patients with pancreatic cancer, along with their CA19-9 and hematocrit data, were analyzed. Each patient underwent preoperative CRT with a prescription of 50.4 Gy in 28 fractions. The patients were chosen based on the presence of a solid tumor in the pancreas that could be clearly delineated. A region of interest (ROI) was placed in the tumor and in the aorta. From the ratio of the iodine density calculated from the DECT in the ROI and the hematocrit taken at the time of simulation, the ECVf was calculated. The ECVf was then compared with the change in CA19-9 before and after the CRT. Distant metastases as the cause of CA19-9 elevation were ruled out on subsequent restaging images before surgery. The DECT-derived iodine ratio was validated using a phantom study. RESULTS: The DECT-derived iodine concentration agreed with the phantom measurements (R2, 1.0). The average hematocrit, ECVf, and change in CA19-9 during the treatment for the 25 patients was 35.6 ± 5.4%, 7.3 ± 4.9%, and -4.6 ± 21.8 respectively. A linear correlation was found between the ECVf and the change in CA19-9, with an R2 of 0.7: ΔCA19-9 = 3.63 × ECVf - 31.1. The correlation was statistically significant (P = .006). CONCLUSIONS: The calculated ECV fraction based on iodine maps from dual-source DECT may be used to predict treatment response after neoadjuvant chemoradiation therapy for pancreatic cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Noid G, Godfrey G, Hall W, et al. Predicting Treatment Response From Extracellular Volume Fraction for Chemoradiation Therapy of Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 36210026. doi:10.1016/j.ijrobp.2022.09.084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。